Mikhael Nancy W, El Latif Walid Abd, Elhabak Doaa M
Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University, Benha, Al Qalyubia Governorate, Egypt.
Clinical and Chemical Pathology, Faculty of Medicine, Benha University, Benha, Al Qalyubia Governorate, Egypt.
Indian J Dermatol. 2021 May-Jun;66(3):329. doi: 10.4103/ijd.IJD_658_19.
Lichen planus (LP) is an immune mediated inflammatory condition. SCCAII is a useful biomarker reflecting Th17 type inflammation. It is also a tumour marker, especially for Squamous cell carcinoma (SCC) Mechanism of carcinogenesis in LP is still unknown. Chronic inflammation may facilitate the development of cellular clones in the epidermis.
Estimation of serum level of SCCA II in patients with cutaneous and oral LP (OLP) to detect its role in LP pathogenesis, and to reveal the missing link in understanding mechanism of carcinogenesis in LP.
A case control study, where 100 subjects were included; 80 LP patients (40 cutaneous & 40 oral) and 20 apparently healthy controls. We obtained an informed written consent from each subject prior the participation. Cutaneous and oral LP were diagnosed clinically, SCCA II level was measured by ELISA technique.
Statistical analysis was done using SPSS vs.25. (IBM, Armonk, New York, United states). Numerical data was summarized as means and standard deviations or medians and ranges.
Median SSCCAII level was significantly higher in LP cases compared to controls ( < 0.001) and was significantly higher in patients with OLP compared to patients with cutaneous LP ( ≤ 0.001). Post hoc analysis revealed that median SSCCAII was significantly higher in patients with ulcerative type compared to both reticular type and others. It was also significantly higher in patients with actinic type compared to both hypertrophic type and classic type. Median SSCCAII was significantly higher in patients with ulcerative OLP compared to actinic LP ( < 0.001).
Our study revealed that serum SCCAII level was higher in patients with cutaneous and OLP. This might be linked to the pathogenesis of LP, especially actinic and erosive OLP. SCCAII level could facilitate the screening and early detection of patients at risk, a potential alarm to launch accurate assessment and continue follow up of cutaneous as well as O LP patients.
扁平苔藓（LP）是一种免疫介导的炎症性疾病。SCCAII是反映Th17型炎症的一种有用的生物标志物。它也是一种肿瘤标志物，尤其对于鳞状细胞癌（SCC）。LP的致癌机制尚不清楚。慢性炎症可能促进表皮细胞克隆的发展。
评估皮肤型和口腔扁平苔藓（OLP）患者血清SCCA II水平，以检测其在LP发病机制中的作用，并揭示LP致癌机制中缺失的环节。
一项病例对照研究，纳入100名受试者；80例LP患者（40例皮肤型和40例口腔型）和20名明显健康的对照者。在每位受试者参与之前，我们获得了他们的知情书面同意。皮肤型和口腔型LP通过临床诊断，SCCA II水平通过ELISA技术测量。
使用SPSS 25.0（美国纽约州阿蒙克市IBM公司）进行统计分析。数值数据总结为均值和标准差或中位数和范围。
与对照组相比，LP病例的SCCAII中位数水平显著更高（<0.001），与皮肤型LP患者相比，OLP患者的SCCAII中位数水平显著更高（≤0.001）。事后分析显示，与网状型和其他类型相比，溃疡型患者的SCCAII中位数显著更高。与肥厚型和经典型相比，光化型患者的SCCAII中位数也显著更高。与光化型LP相比，溃疡型OLP患者的SCCAII中位数显著更高（<0.001）。
我们的研究表明，皮肤型和OLP患者的血清SCCAII水平更高。这可能与LP的发病机制有关，尤其是光化型和糜烂型OLP。SCCAII水平有助于对高危患者进行筛查和早期检测，是对皮肤型和OLP患者进行准确评估和持续随访的潜在警示信号。
